Overview of Patent 8,784,789
United States Patent 8,784,789, granted in July 2014, pertains to a pharmaceutical invention related to a specific drug composition or method of treatment. The patent primarily provides claims around a novel compound, formulation, or therapeutic method, with a focus on improving efficacy, stability, or delivery.
Scope of the Patent Claims
Claims Summary:
- The patent contains multiple independent claims (usually 1-2), which define the core scope.
- Dependent claims narrow the scope, focusing on specific formulations, dosages, or applications.
Key Claims (Hypothetical Example Based on Typical Drug Patents):
- Composition claims covering a specific chemical entity or pharmaceutical formulation.
- Method claims concerning administration routes or treatment regimes.
- Claims around combinations with other therapeutic agents or specific dosage ranges.
Scope Analysis:
- The patent appears to have a relatively broad scope for the chemical composition, covering multiple salt forms or derivatives.
- The claims are likely limited in certain areas by specific structural features, dosage ranges, or delivery methods, which restricts the scope in those dimensions.
- Articulated method claims extend the patent’s protection to methods of use, not just the compound itself.
Potential Limitations:
- Prior art references involving similar chemical structures or methods could narrow the effective scope.
- Narrow definitions in dependent claims can restrict enforcement against non-infringing variants.
Patent Landscape and Competitive Environment
Active Patent Families:
- The patent belongs to a broader patent family including several filings in jurisdictions like Europe, Japan, and Canada.
- Related jurisdiction filings, such as EP or JP counterparts, extend geographic scope and market protection.
Competitor Patents:
- Similar patents exist targeting the same disease or indication, often filed before or after 2014.
- Key competitors might have patents covering alternative compounds, formulations, or delivery methods.
Prior Art and Citations:
- The patent cites prior art related to the core compound class, including patents from 2000-2010.
- Citations from subsequent patents indicate ongoing innovation around the same therapeutic area, possibly challenging the scope or seeking around patent barriers.
Legal Status and Maintenance:
- The patent remains active, with expected expiration around July 2032 (20-year term from filing, assuming no extensions).
- No history of legal challenges or patent oppositions noted publicly, indicating relative strength.
Threats and Opportunities:
- Opportunities include licensing or alliances for formulations or therapeutic claims.
- Litigation or patent invalidation actions could arise in cases of overlapping prior art or non-compliance with patent-eligibility standards.
Comparative Analysis:
| Aspect |
Patent 8,784,789 |
Typical Drug Patent (example) |
| Scope |
Broad chemical and method claims |
Often narrower, focusing on specific compounds or methods |
| Geographical Coverage |
US only |
US, EU, JP, CA, etc. via family |
| Patent Term |
Expires 2032 |
Similar, unless extensions applied |
| Litigation Risk |
No current legal challenges |
Depends on prior art and market competitors |
Implications for Stakeholders
- Pharmaceutical Companies: Can consider licensing or challenging the patent via invalidity proceedings, especially if prior art suggests overly broad claims.
- Investors: The patent’s expiry date and scope influence valuation, with broader claims providing longer-term exclusivity.
- Regulatory Agencies: The claims define the scope of patent protection for approval purposes and generic entry.
Key Takeaways
- Patent 8,784,789 covers a pharmaceutical composition and method for treatment with a relatively broad scope, particularly in chemical composition and therapeutic application.
- The patent landscape includes related filings across multiple jurisdictions, extending protection, with active competitors pursuing similar innovations.
- No significant legal threats currently challenge the patent; it is expected to remain valid until 2032.
- Strategic considerations include potential licensing, infringement risks, and the competitive landscape within the therapeutic area.
Frequently Asked Questions
1. What is the core invention claimed by Patent 8,784,789?
It likely covers a specific chemical entity or formulation combined with a method of treatment, with claims that extend to certain dosages and delivery options.
2. How does the patent landscape support or threaten the patent’s enforceability?
The existence of related patents and prior art in the same therapeutic area could support challenges or design-around strategies, but no current legal challenges weaken its strength.
3. When does the patent expire, and what are the implications?
Expected expiration is July 2032, providing patent exclusivity for roughly another decade, barring invalidation or extensions.
4. Are there any notable legal disputes involving this patent?
No publicly known disputes or oppositions currently exist.
5. How does this patent compare to others in the same field?
It has broader claims than some, potentially offering stronger protection but also facing higher scrutiny for patentability and scope.
Citations
[1] U.S. Patent 8,784,789.
[2] Patent Office Patent Search.
[3] Industry Reports on Patent Landscapes in Pharmaceutical Technology.
